Mesothelioma
213
37
54
80
Key Insights
Highlights
Success Rate
67% trial completion
Published Results
44 trials with published results (21%)
Research Maturity
80 completed trials (38% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
18.8%
40 terminated out of 213 trials
66.7%
-19.9% vs benchmark
6%
12 trials in Phase 3/4
55%
44 of 80 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 80 completed trials
Clinical Trials (213)
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
A Phase 3 Trial in Advanced Epithelioid Mesothelioma
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin